We are a dedicated plant-based research and biopharmaceutical drug development company.
Our goal is to create patented formulations of plant-inspired, minimum essential mixtures for use as prescription medications.
We achieved statistically significant results in our Animal Proof-of-Concept Study, and the US Patent was issued in 2020. Our goal is to begin our First-in-Man trial as soon as possible.
GB Sciences Signs Licensing Deal With EndoPure Life Sciences for 5% Gross Sales Royalty & Sponsorship of First-in-Human Trial for Their Cannabinoid-Based Parkinson’s Drug
GBLX’s novel drug discovery program produced 8 issued US and 14 issued global patents, as well as 15 US and 51 global patent-pending applications. We have 5 preclinical phase drug programs in our pipeline, and our Parkinson’s therapeutics are being prepared for a First-in-Human trial.
The strength of our R & D pipeline has been the participation of world class researchers from 9 international universities over the past 7 years. Together, we have assembled the ultimate toolkit to create the future of medicine; AI technology, plant-based medicine, and hard sciences.
Translating new drug principles into real world medicines requires expertise in several disciplines. Our partners help make our dream of novel plant-inspired medicines a reality by providing expertise in cGMP-certified active ingredients and novel oral delivery methods.
Our Goal is to preserve the efficacy of plant-based medicines while reducing their complexity for standardization.
Our Strategy is to combine our proprietary PhAROS Drug Discovery Platform and High Throughput Screening of Cell and Animal Models of Specific Disease Processes to Create Rationally-Designed, Minimum Essential Mixtures.
Press Release Oct 15, 2024 07:00 EDT As a part of their Exclusive Licensing Deal, EndoPure Life Sciences will finance and sponsor first-in-human clinical trials,
Potential use for chronic pain: Poly(Ethylene Glycol)-Poly(Lactic-Co-Glycolic Acid) nanoparticles enhance the effects of Cannabis-Based terpenes on calcium influx in TRPV1-Expressing cells
